HOME >> MEDICINE >> NEWS
Long-term outcomes for prostate cancer show IMRT Curative: 89 percent disease-free 8 years later

ent with neoadjuvant androgen deprivation.

Between April 1996 and January 2000, 561 patients with a median age of 68 (ranging from 46 to 86 years old) were treated with IMRT, an improved form of three-dimensional conformal radiation therapy (3D-CRT), also used in radiotherapy. IMRT uses enhanced planning treatment software that more precisely targets the prostate, allowing the beam of radiation to deliver a high dose (81 Gy) to the tumor target while sparing the adjacent bladder and rectum from exposure to the higher amounts of radiation. Perhaps because of this, the eight-year results show urinary continence was maintained for all patients, and only 1.6 percent of the five hundred sixty-one patients experienced rectal bleeding. The high-dose radiotherapy was curative for the majority of the patients in all three prognostic risk groups, with 89 percent of the favorable, 78 percent of the intermediate, and 67 percent of the unfavorable group alive after an average period of eight years. Of those men who were potent prior to IMRT, erectile dysfunction developed in 49 percent.

"This study confirms that we can improve patients' quality of life by reducing the side effects of radiotherapy while maintaining disease-free survival," said Dr. Zelefsky. "However, there is still room for improvement. We are incorporating image-guided approaches that may continue the excellent tumor control but further limit the area we are irradiating and reduce side-effects."


'"/>

Contact: Joanne Nicholas
nicholaj@mskcc.org
212-639-3137
Memorial Sloan-Kettering Cancer Center
27-Sep-2006


Page: 1 2

Related medicine news :

1. Long-term treatment with VYVANSE, first prodrug stimulant, demonstrates significant efficacy in ADHD
2. Long-term anti-clotting therapy sweetens stenting outcomes in diabetic patients
3. Long-term aspirin use associated with reduced risk of dying in women
4. Long-term data on safety and effectiveness of antiobesity drugs needed
5. Long-term financial costs associated with prostate cancer treatment
6. Long-term effects of non-alcoholic fatty liver disease
7. Long-term abstinence may resolve many of the neurocognitive deficits associated with alcoholism
8. Long-term safety results released for breast cancer drugs
9. Long-term ibuprofen regimen after brain injury worsens cognition in animal study
10. Media availability: Long-term survival of heart attack patients with shock
11. Long-term estrogen therapy linked to breast cancer risk

Post Your Comments:
(Date:2/27/2015)... Mequon, Wisconsin (PRWEB) February 27, 2015 ... facial plastic surgeons , is pleased to announce the ... location now open in Delafield. Quintessa has begun seeing ... Campbell, the new Delafield location will offer a variety ... patients, including: Botox, filler injectables, micro laser peels, chemical ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 Legislation ... Committee, includes a pharmacy provision to help prevent ... the pharmacy counter. The Protecting the Integrity of ... Health Subcommittee Chairman Kevin Brady (R-TX) and Ranking ... address the prescription drug abuse epidemic and implement ...
(Date:2/27/2015)... The winter season is here, and with ... mold grows, it can be harmful to the home and ... consequences of mold growth with the help of Enviro-Test. Enviro-Test, ... on the best ways to prevent mold during the winter ... conditions for mold to thrive. Mold must be removed properly, ...
(Date:2/27/2015)... FACE Skincare~Medical~Wellness, a multiaward-winning leader in ... combination to take fifteen years off of an ... new treatment introduced that is the first and ... improve lines and wrinkles on the Décolleté. This ... from the stubborn vertical lines between the upper ...
(Date:2/27/2015)... February 27, 2015 The UC Davis ... expertise have made it a beacon of hope for ... has been acknowledged by the national society committed to ... Huntington’s Disease Society of America — as a Level ... acknowledgement recognizes the center’s service to over 300 families ...
Breaking Medicine News(10 mins):Health News:Dr. Andrew Campbell Expands Quintessa Aesthetic Center into Delafield 2Health News:Dr. Andrew Campbell Expands Quintessa Aesthetic Center into Delafield 3Health News:PCMA Statement on the ‘Protecting the Integrity of Medicare Act’ 2Health News:Enviro-Test Offers Tips for Winter Mold Prevention 2Health News:Face Skincare Announces New Combination Therapy 2Health News:UC Davis Huntington's Disease Center Receives Level 1 Designation 2Health News:UC Davis Huntington's Disease Center Receives Level 1 Designation 3
(Date:2/27/2015)... 27, 2015  Boston Scientific Corporation (NYSE: ... 2015 Annual Healthcare Conference on March 10 in ... Brennan , executive vice president and chief financial officer, ... will participate in a 25-minute question and answer session ... 1:05 p.m. ET. Following a 5-minute break, a question ...
(Date:2/27/2015)... SOUTH PLAINFIELD, N.J., Feb. 27, 2015  PTC Therapeutics, ... corporate update and reported financial results for the fourth ... "2014 was a transformative year for PTC. ... on delivering and developing RNA-targeted therapies in the rare ... Officer, PTC Therapeutics, Inc. "We are proud to bring ...
(Date:2/27/2015)... and JERUSALEM , Feb. 27, 2015 ... octreotide capsules, its lead product for the orphan condition ... Series E financing round. Participants in the financing included ... an undisclosed blue chip public investment fund, as well ... Health Ventures, Abingworth and ARCH Venture Partners. ...
Breaking Medicine Technology:Boston Scientific to Participate in the Barclays 2015 Annual Healthcare Conference 2PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 10PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 11Chiasma Announces Completion of $70 Million Series E Financing 2Chiasma Announces Completion of $70 Million Series E Financing 3
Cached News: